In addition, the influence of hormones, sex differences in immunity, and complexity of the regulatory mechanism in tumor angiogenesis may also contribute to the different roles of stains, ezetimibe and PCSk9 inhibition in breast cancer and prostate cancer [39, 40, 43]. Here, PCSK9 is linked to prostate cancer.